Engineering fully human monoclonal antibodies from murine variable regions.
about
Structural Basis for Treating Tumor Necrosis Factor (TNF )-associated Diseases with the Therapeutic Antibody InfliximabComparison of the Inhibition Mechanisms of Adalimumab and Infliximab in Treating Tumor Necrosis Factor α-Associated Diseases from a Molecular ViewTowards engineering hormone-binding globulins as drug delivery agentsInfluence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review.Topical antimicrobials for burn infections - an updateMAPs: a database of modular antibody parts for predicting tertiary structures and designing affinity matured antibodiesAugmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.Cloning and sequencing of the light chain variable region from NS-1 myeloma.Engineering the variable region of therapeutic IgG antibodies.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Microbials for the production of monoclonal antibodies and antibody fragments.Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.Extracting human antibody sequences from public databases for antibody humanization: high frequency of species assignment errors.Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys.Construction of a human monoclonal antibody against bFGF for suppression of NSCLC.
P2860
Q27676857-52AA816E-1103-40ED-8DC8-231B5620398AQ27679553-3F2E106A-1239-45B3-A92B-5C9F328AF945Q28545213-7227D739-4A2F-4689-B3C3-6B9D9BBE8CB1Q30240229-2DD79645-2981-4CE2-8012-6BF3CD95E936Q33600002-B6B006A6-9DA0-4438-BB9D-3AD7F718F966Q34746957-30CB845C-FE6F-469A-936C-502F7078C825Q35856534-833BC453-ED54-46FB-855C-9ACE9E14E53FQ36076051-A12F0793-A163-454A-B5A3-9AD8B83ACCB0Q37853324-74E3BD80-BD5F-4332-9B05-748F2D0AFBBBQ38017581-9A738260-B8D2-473A-829A-B2697BC3F50DQ38159015-59633569-595D-4B51-84B2-9E354C167052Q38575679-D9A0A1BD-DBEC-48E9-86CB-72B09B985D70Q46535975-9C163B35-0308-48F5-9EDC-D9848676D6A0Q49592680-F22CB4CE-4CB2-49A5-94F7-7A7BE1D055CBQ50926502-1830AB27-5135-4DDF-975A-F342FC17D1D2Q55473120-AC0108AF-04FA-4961-97DE-1E7E3C81428C
P2860
Engineering fully human monoclonal antibodies from murine variable regions.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Engineering fully human monoclonal antibodies from murine variable regions.
@ast
Engineering fully human monoclonal antibodies from murine variable regions.
@en
Engineering fully human monoclonal antibodies from murine variable regions.
@nl
type
label
Engineering fully human monoclonal antibodies from murine variable regions.
@ast
Engineering fully human monoclonal antibodies from murine variable regions.
@en
Engineering fully human monoclonal antibodies from murine variable regions.
@nl
prefLabel
Engineering fully human monoclonal antibodies from murine variable regions.
@ast
Engineering fully human monoclonal antibodies from murine variable regions.
@en
Engineering fully human monoclonal antibodies from murine variable regions.
@nl
P2093
P1476
Engineering fully human monoclonal antibodies from murine variable regions.
@en
P2093
Duc-Hanh T Nguyen
Greg A Lazar
Gregory L Moore
Hsing Chen
Irene W L Leung
John R Desjarlais
Jonathan Jacinto
Jonathan Zalevsky
Matthew J Bernett
P304
P356
10.1016/J.JMB.2009.12.046
P407
P577
2010-01-04T00:00:00Z